To help define the most important corporate responsibility (CR) issues for Novartis, the company completed a CR materiality analysis in 2013. The term “CR materiality” is a measure of how important CR issues are to the company and our stakeholders.
In 2015, we conducted a review of our materiality analysis with our external stakeholders. This confirmed the results of our 2013 exercise.
We plan to use the findings of our CR materiality exercise to guide our strategy, track issues of concern, inform and prioritize our CR programs, and establish meaningful metrics against which to measure our CR performance.